DRUG NAME: Abiraterone - BC Cancer

Abiraterone Caution: Use caution in patients with: • mineralocorticoid excess1; see paragraph following Side Effects table • hypokalemia1; see paragraph following Side Effects table • cardiovascular disease (e.g. uncontrolled hypertension, myocardial infarction, arterial thrombosis , unstable angina or reduced left ventricular ejection fraction, LVEF < 50%)1

  Name, Drug, Drug name, Abiraterone

BC Cancer Protocol Summary for Palliative Therapy for ...

BC Cancer Protocol Summary for Palliative Therapy for Metastatic Castration Resistant Prostate Cancer Using Abiraterone and predniSONE . Protocol Code:

  Therapy, Resistant, Prostate, Cancer, Palliative, Metastatic, Abiraterone, Castration, Palliative therapy for metastatic castration resistant prostate cancer

abiraterone acetate NEW ZEALAND DATA SHEET

CCDS 170321 4 ZYTIGA(180620)ADS Abiraterone is a substrate of CYP3A4. The effects of strong CYP3A4 inhibitors or inducers on the pharmacokinetics of abiraterone have not been investigated.

  Abiraterone

Assessment report - European Medicines Agency

Xtandi Assessment report EMA/CHMP/607459/2014 Page 3/92 List of abbreviations Abbreviation Definition BPI Brief Pain Inventory Short Form

  Assessment, Report, Assessment report

List of Designated High-Cost Drugs for Reduced ...

List of Designated High-Cost Drugs for Reduced Pharmaceutical Distribution Effective October 18, 2018 Page 1 of 2 DIN Chemical Description Product Name